Complete remission rate (CRR) was the primary end point of the trial and did not differ between the 500 mg (32%) and 1,000 mg (50%) cohort with a statistical trend in favor of the latter.
← all excerpts
Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia.
1
—
—